Seres Therapeutics Inc (NASDAQ:MCRB) finished Thursday with a subtraction of $0.0 to close at $2.39, a downside of 0.00 percent. An average of 2,730,980 shares of common stock have been traded in the last five days. There was a fall of -$0.33 in the past week, and it reached a new high 9 times over the past 12 months. The last 20 days have seen an average of 2,320,680 shares traded, while the 50-day average volume stands at 2,152,142.
MCRB stock has decreased by -32.87% in the last month. The company shares reached their 1-month lowest point of $2.28 on 09/28/23. With the stock rallying to its 52-week high on 04/18/23, shares of the company touched a low of $2.31 and a high of $9.49 in 52 weeks. It has reached a new high 6 times so far this year and lost -57.32% or -$3.21 in price. In spite of this, the price is down -74.82% from the 52-week high.
Insider Transactions
MCRB stock investors should be aware that Seres Therapeutics Inc (MCRB) stock had its last reported insider trading activity 154 days ago on Apr 28. In this transaction, the insider spent $36,527., Ege David S., disposed of 5,012 shares at a price of $7.93 on Oct 31. The insider now owns more than $39,745 worth of shares.
Valuation Metrics
Seres Therapeutics Inc (MCRB) stock’s beta is 2.69. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 2.35, the price-to-book (PB) ratio at 13.53.
Financial Health
The quick ratio of Seres Therapeutics Inc for the three months ended June 29 was 3.16, and the current ratio was 3.23, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 9.18 and a total debt to equity ratio of 9.42 for the quarter ending June 29. Seres Therapeutics Inc’s EBITDA margin for the year ending June 29 is -3277.68%, while its operating margin for the same period stands at -108.18%. Its gross profit as reported stood at $253.62 million compared to revenue of $7.13 million.
Earnings Surprise
For the three-month period that ended June 29, Seres Therapeutics Inc had $100.74 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $46.55 million in the quarter, while revenues of -$71.17 million were grew 239.08%. The analyst consensus anticipated Seres Therapeutics Inc’s latest quarter earnings to come in at $0.53 per share, but it turned out to be $0.36, a -32.10% surprise. For the quarter, EBITDA amounted to $51.15 million. Shareholders own equity worth $128.21 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Seres Therapeutics Inc (MCRB) price momentum. RSI 9-day as of the close on 28 September was 18.83%, suggesting the stock is oversold, with historical volatility in this time frame at 49.07%.
As of today, MCRB’s price is $2.43 -12.13% or -$0.33 from its 5-day moving average. MCRB is currently trading -32.29% lower than its 20-day SMA and -59.56% lower than its 100-day SMA. However, the stock’s current price level is -49.36% below the SMA50 and -63.46% below the SMA200.
The stochastic %K and %D were 7.08% and 4.44%, respectively, and the average true range (ATR) was 0.17. With the 14-day stochastic at 11.46% and the average true range at 0.18, the RSI (14) stands at 20.72%. The stock has reached -0.19 on the 9-day MACD Oscillator while the 14-day reading was at -0.34.
Analyst Ratings
The consensus rating for Seres Therapeutics Inc (MCRB) among analysts is Overweight. According to current brokerage recommendations, 1 brokerage firm advise that investors sell MCRB, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 5 others rate it as a “buy”.
What is MCRB’s price target for the next 12 months?
Analysts predict a range of price targets between $4.00 and $15.00, with a median target of $11.00. Taking a look at these predictions, the average price target given by analysts for Seres Therapeutics Inc (MCRB) stock is $9.83.
